about
Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis.Microglia induce motor neuron death via the classical NF-κB pathway in amyotrophic lateral sclerosis.Microarray analysis of the cellular pathways involved in the adaptation to and progression of motor neuron injury in the SOD1 G93A mouse model of familial ALS.Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS).Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis.SRSF1-dependent nuclear export inhibition of C9ORF72 repeat transcripts prevents neurodegeneration and associated motor deficits.Delayed disease onset and extended survival in the SOD1G93A rat model of amyotrophic lateral sclerosis after suppression of mutant SOD1 in the motor cortexTranscriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis.Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones.Lysosomal and phagocytic activity is increased in astrocytes during disease progression in the SOD1 (G93A) mouse model of amyotrophic lateral sclerosis.MicroNeurotrophins Improve Survival in Motor Neuron-Astrocyte Co-Cultures but Do Not Improve Disease Phenotypes in a Mutant SOD1 Mouse Model of Amyotrophic Lateral Sclerosis.Translational profiling identifies a cascade of damage initiated in motor neurons and spreading to glia in mutant SOD1-mediated ALS.Oligodendrocytes contribute to motor neuron death in ALS via SOD1-dependent mechanism.Therapeutic AAV9-mediated suppression of mutant SOD1 slows disease progression and extends survival in models of inherited ALSDirect conversion of patient fibroblasts demonstrates non-cell autonomous toxicity of astrocytes to motor neurons in familial and sporadic ALSAdditive amelioration of ALS by co-targeting independent pathogenic mechanisms.Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis.Gene expression profiling in human neurodegenerative disease.Dysregulation of astrocyte-motoneuron cross-talk in mutant superoxide dismutase 1-related amyotrophic lateral sclerosis.New In Vitro Models to Study Amyotrophic Lateral Sclerosis.The non-cell-autonomous component of ALS: new in vitro models and future challenges.High content analysis in amyotrophic lateral sclerosis.The C9orf72 protein interacts with Rab1a and the ULK1 complex to regulate initiation of autophagy.Neural stem cells as a therapeutic approach for amyotrophic lateral sclerosis.Differences in protein quality control correlate with phenotype variability in 2 mouse models of familial amyotrophic lateral sclerosis.Gene delivery improvement for treating the lysosomal storage disorder metachromatic leukodystrophy.Can Astrocytes Be a Target for Precision Medicine?Translating SOD1 Gene Silencing toward the Clinic: A Highly Efficacious, Off-Target-free, and Biomarker-Supported Strategy for fALS.Ursodeoxycholic Acid Improves Mitochondrial Function and Redistributes Drp1 in Fibroblasts from Patients with Either Sporadic or Familial Alzheimer's DiseaseOUP accepted manuscriptTranscriptional response of the neuromuscular system to exercise training and potential implications for ALSAstrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosisMicro-RNAs secreted through astrocyte-derived extracellular vesicles cause neuronal network degeneration in C9orf72 ALS
P50
Q30277241-B5B86AED-21DA-4500-8867-FEDB668F6CD2Q30575638-A787BE07-427C-4F01-90A6-1351A441032BQ33294971-1F2C9282-3DCD-4C68-AF9D-72121DA59734Q33749062-67BF569B-C5DB-4019-91FC-A215ACBCDEB2Q33791649-B29A6284-6F7F-45AF-BEE1-CE73F7670F2AQ33891056-3FAE976D-156C-4BF1-BF24-71CF839DB5FEQ34983540-C269CB28-DCDC-41EE-8204-90D7DE522BB2Q34996837-72D10B7F-C32B-458F-8ECA-C937440D1826Q35153080-04080218-AA7E-4A8C-ADCD-B43A7445F5F7Q35153466-94178253-76DD-4508-870C-D7F16B09F0D5Q35830165-9E48EBAD-1C53-41FF-8791-0826CC434F12Q36157573-8BD4006F-1E57-4851-A4C1-CFFCE46E98E6Q36394283-E2EF5901-EBE7-4AB2-92B0-98075FFE1489Q37369313-0079336C-55AC-48D1-BAB9-C23A83C0F9B6Q37393810-4CC2C32F-9FB0-4606-9B7F-C15C31F9E1EDQ37495227-FFB8559B-6035-41E0-87C6-65770E990F7BQ37620170-A92D049E-3E08-4C59-B1F7-8C5842AF406EQ37952528-BD1BA484-C7EE-40F0-9821-D1909D0AD48FQ38034387-4A0ACB94-7A44-45C7-A60F-0821B8587B1FQ38366741-C6539C51-813F-405C-96BE-175F59AFAB8DQ38701237-BF519D33-033E-4A52-B24C-5796366EB934Q38955367-FEDCB7CA-F083-493B-BECF-83808CF54DDDQ39037865-591B713C-44AD-40EA-B1F2-1FA11A8DEF15Q39662062-8DCD3E21-1049-40E9-99C4-34427A019086Q41574283-210B7C6E-D0D2-4500-A4AF-2247BD1391F7Q42463390-176F451C-053D-4308-8C02-D90F73F75F5AQ45881221-7A3E6C5B-5400-4B72-9069-57612A50B3DDQ48140499-A78EC70D-6A9D-459F-B8A4-94FAABFE770DQ55399094-BBAEC0DF-5052-493C-BA33-576DE4702795Q57479995-0D795350-EC6A-4BFC-AC75-6CC0CA1AFA60Q59544259-8D88C27D-1157-4F0A-82D1-E795A72F95E4Q59544312-D4485B73-5D67-4F61-A922-1A4ED6393600Q64230186-3C95BFF4-DC75-4F80-8113-CD7B0FB44218Q64261334-6665C0CD-22C5-4F59-872D-12EEB22E0358
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Laura Ferraiuolo
@ast
Laura Ferraiuolo
@en
Laura Ferraiuolo
@es
Laura Ferraiuolo
@nl
Laura Ferraiuolo
@sl
type
label
Laura Ferraiuolo
@ast
Laura Ferraiuolo
@en
Laura Ferraiuolo
@es
Laura Ferraiuolo
@nl
Laura Ferraiuolo
@sl
prefLabel
Laura Ferraiuolo
@ast
Laura Ferraiuolo
@en
Laura Ferraiuolo
@es
Laura Ferraiuolo
@nl
Laura Ferraiuolo
@sl
P1053
E-5834-2010
P106
P1153
19933343900
P21
P2798
P31
P3829
P496
0000-0001-9118-5714